Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma

This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural mesothelioma. Phase 1b evaluates the candidate recommended Phase 2 dose (RP2D), followed by Phase 2 evaluation at the confirmed RP2D.

Trial Details

NCT ID
NCT07885319
Phase
PHASE1 / PHASE2
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Ivonescimab Combined With Chemotherapy
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Age 18 to 75 years.
  • Histologically confirmed advanced or metastatic malignant pleural mesothelioma not amenable to surgery.
  • No prior systemic anticancer therapy for advanced disease.
  • ECOG PS 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →